logo BDSP

Base documentaire

  1. A cost-effectiveness analysis of cognitive behavior therapy and fluoxetine (prozac) in the treatment of depression : Cost-effectiveness, cost-benefits, and quality of life.

    Article - En anglais

    Depression affects at least 11 million Americans per year and costs the U.S. economy an estimated 44 billion dollars annually.

    Comprehensive review of the existing scientific evidence suggests that psychotherapy, particularly cognitive behavior therapy (CBT), is at least as effective as medication in the treatment of depression, even if severe (Antonuccio, Danton, & DeNelsky, 1995).

    These conclusions hold for both vegetative and social adjustment symptoms, especially when patient-rated measures are used and long-term follow-up is considered.

    In addition, several well-controlled studies with long-term follow-up (Evans et al., 1992 ; Shea et al., 1992 ; Simons, Murphy, Levine, & Wetzel, 1986) suggest that CBT may be more effective than drug treatment at preventing relapse.

    The relative effectiveness of psychotherapy for depression, particularly CBT, has been reinforced by meta-analyses reported in both psychiatry (Hollon, Shelton, & Loosen, 1991 ; Wexler & Cicchetti, 1992) and psychology journals (Dobson, 1989 ; Robinson, Berman, & Neimeyer, 1990 ; Steinbrueck, Maxwell, & Howard, 1983).

    In the era of managed care, it is not enough to be effective ; treatments must be cost-effective.

    This paper considers the outcome studies as the basis for a cost-effectiveness comparison of drugs and psychotherapy in the treatment of unipolar depression. (...)

    Mots-clés Pascal : Analyse coût efficacité, Thérapie comportementale, Fluoxétine, Etat dépressif, Trouble humeur, Etude comparative, Traitement associé, Efficacité traitement, Economie santé, Homme, Inhibiteur recapture, Sérotonine, Psychotrope, Antidépresseur

    Mots-clés Pascal anglais : Cost efficiency analysis, Behavior therapy, Fluoxetine, Depression, Mood disorder, Comparative study, Combined treatment, Treatment efficiency, Health economy, Human, Reuptake inhibitor, Serotonin, Psychotropic, Antidepressant agent

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 97-0509953

    Code Inist : 002B18I06. Création : 13/02/1998.